Gel formulations for guiding radiotherapy

Abstract

The present invention describes an X-ray contrast composition for local administration, wherein the X-ray contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body.

1 . An imaging contrast composition for local administration, wherein the imaging contrast composition exhibits contrast properties and wherein at least 60% of an administrated amount of said imaging contrast composition remains more than 24 hours within 10 cm from an injection point when the imaging contrast composition is administrated to a human or animal body. 
     
     
         2 . The imaging contrast composition according to  claim 1 , wherein the imaging contrast composition is an X-ray contrast composition, and wherein the X-ray contrast composition is a liquid before administration and having the ability to transform into a gel after administration. 
     
     
         3 . (canceled) 
     
     
         4 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition is a liquid before administration into a human or animal body that increases in viscosity by more than 1,000 centipoise (cP) after administration into a human or animal body. 
     
     
         5 . (canceled) 
     
     
         6 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition has a viscosity of less than 10,000 centipoise (cP) at 20° C. 
     
     
         7 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises an X-ray contrast agent that is part of the X-ray contrast composition and said X-ray contrast agent is an organic sub stance. 
     
     
         8 . The imaging contrast agent according to  claim 2 , wherein the X-ray contrast agent comprises one or more natural polymers, synthetic polymers, oligomers, lipids, saccharides, disaccharides, polysaccharides, peptides or any combination thereof, or wherein the X-ray contrast agent comprises one or more iodinated polymers, oligomers, lipids, saccharides, disaccharides, polysaccharides, peptides, or a derivative or a combination thereof. 
     
     
         9 - 13 . (canceled) 
     
     
         14 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition exhibits gel-formation in response to a temperature in the range of 35 to 40° C., in response to hydration, in response to an ion-concentration in the range of 1 μM to 500 mM, in response to a pH in the range of 6 to 8 and or in response to contacting with an initiator. 
     
     
         15 - 18 . (canceled) 
     
     
         19 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition also comprises, radioactive compounds, paramagnetic compounds, fluorescent compounds or ferromagnetic compounds, or any mixture thereof, and/or wherein the X-ray contrast composition also comprises at least one pharmaceutical substance. 
     
     
         20 - 24 . (canceled) 
     
     
         25 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises poly(ethylene glycol-b-caprolactone) (PEG-PC1), sucrose acetate isobutyrate (SAIB), poly(D,L-lactic acid), or poly(lactic-co-glycolic acid) (PGLA), or a combination thereof. 
     
     
         26 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises sucrose acetate isobutyrate (SAIB) or a derivative thereof. 
     
     
         27 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB) or an iodinated derivate of sucrose acetate isobutyrate (SAIB) doped into sucrose acetate isobutyrate (SAIB). 
     
     
         28 . (canceled) 
     
     
         29 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB) solubilized in a mixture of ethanol and sucrose acetate isobutyrate (SAIB). 
     
     
         30 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB) and contains a pharmaceutical substance or particle that contains a pharmaceutical substance. 
     
     
         31 . (canceled) 
     
     
         32 . The imaging contrast composition according to  claim 2 , wherein the X-ray contrast composition comprises an iodinated derivate of sucrose acetate isobutyrate (SAIB) solubilised in a mixture of ethanol and sucrose acetate isobutyrate (SAIB) and contains a pharmaceutical substance or a particle that contains a pharmaceutical substance. 
     
     
         33 . (canceled) 
     
     
         34 . A kit comprising a syringe, a needle used for injection into a body or surgical related procedures, such as but not limited to biopsy adapted to the open end of said syringe, and a composition according to  claim 1 . 
     
     
         35 . The imaging contrast composition according to  claim 1 , for use in radio therapy, imaging, diagnostics, treatment and/or quality rating of radio therapy, for use as a tissue marker and/or for use as a controlled drug release composition. 
     
     
         36 - 40 . (canceled) 
     
     
         41 . The imaging contrast composition according to  claim 1 , wherein the imaging contrast composition is parenterally administered to a predetermined location of the body of said mammal, and wherein an X-ray image of at least a part of the body of the mammal including the predetermined location is recorded. 
     
     
         42 . A method of recording an X-ray image of the body of a mammal, comprising the steps of
 a. providing an X-ray contrast composition comprising an organic X-ray agent in a gel-forming system;   b. administering the X-ray contrast composition to a predetermined location of the mammal, and   c. recording X-ray-based images of at least a part of the body which comprises the predetermined location.   
     
     
         43 . A method of joint radiotherapy and X-ray imaging of a target tissue in a mammal, comprising the steps of
 a. providing an X-ray contrast composition comprising an organic X-ray agent in a gel-forming system;   b. administering the X-ray contrast composition to a predetermined target tissue of the mammal,   c. recording X-ray-based images, of at least a part of the body which comprises the target tissue, thereby providing a definition of the target tissue, and   d. using the definition of the target tissue obtained in c) to direct external beam radiotherapy to the target tissue.   
     
     
         44 . A method for directing local administration of a pharmaceutically active agent to a target tissue in a mammal, comprising the steps of
 a. providing an X-ray contrast composition comprising an organic X-ray agent in a gel-forming system;   b. administering the X-ray contrast composition to a predetermined target tissue of the mammal,   c. recording X-ray-based images, of at least a part of the body which comprises the target tissue, thereby providing a definition of the target tissue, and   d. using the X-ray contrast composition in b) to further comprise an active pharmaceutical agent for delivery of an active pharmaceutical agent to a predetermined target tissue of the mammal.   
     
     
         45 . The method according to  claim 43 , wherein the target tissue comprises undesirably growing cells. 
     
     
         46 - 47 . (canceled) 
     
     
         48 . The method according to  claim 42 , wherein the X-ray contrast composition comprises the feature of exhibiting contrast properties and wherein at least 60% of an administrated amount of the X-ray contrast composition remains more than 24 hours within 10 cm from an injection point when the X-ray contrast composition is administrated to a human or animal body, and wherein the X-ray contrast composition is a liquid before administration and has the ability to transform into a gel after administration. 
     
     
         49 . (canceled)